KYKOF:OTC-Kyowa Kirin Co. Ltd (USD)

COMMON STOCK | Drug Manufacturers - General |

Last Closing

USD 20.971

Change

0.00 (0.00)%

Market Cap

USD 11.02B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Kyowa Kirin Co., Ltd. engages in the research, development, manufacturing, marketing, and import/export of pharmaceuticals for oncology, nephrology, central nervous system, and immunology therapeutic areas in Japan, the United States, rest of the Americas, Europe, Asia, and internationally. Its products include ALLELOCK, an antihistamine agent for patients with various types of allergies; CONIEL, a calcium channel blocker for hypertension and angina pectoris; Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; ESPO, a glycoprotein and human erythropoietin; NESP, an erythropoiesis stimulating agent; and GRAN, a human colony-stimulating factor. The company also develops GRAN /Peglasta/Neulasta for chemotherapy-induced febrile neutropenia; LUMICEF, a biological treatment for moderate to severe plaque psoriasis; Moventig, a mu-opioid receptor antagonist for the treatment of opioid induced constipation; Nouriast/ Nourianz, an adenosine receptor antagonist for Parkinson's disease; and ORKEDIA, an oral calcimimetics agent. In addition, it offers POTELIGEO, a humanized monoclonal antibody for CC chemokine receptor 4; REGPARA for the treatment of secondary hyperparathyroidism; and Romiplate/Nplate, a genetically recombinant protein that produces platelet through the stimulation of thrombopoietin receptors. Kyowa Kirin Co., Ltd. has an agreement with Amgen Inc. to jointly develop and commercialize KHK4083, an anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in June 2019. The company was incorporated in 1949 and is headquartered in Tokyo, Japan. Kyowa Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-04 )

Largest Industry Peers for Drug Manufacturers - General

Symbol Name Price(Change) Market Cap
RHHBY Roche Holding Ltd ADR

N/A

USD 258.74B
RHHVF Roche Holding AG Participation

-6.28 (-2.05%)

USD 258.74B
RHHBF Roche Holding AG

N/A

USD 258.74B
AZNCF AstraZeneca PLC

-0.14 (-0.09%)

USD 241.92B
SNYNF Sanofi

N/A

USD 142.76B
CHGCY Chugai Pharmaceutical Co Ltd A..

-0.12 (-0.51%)

USD 83.22B
DSNKY Daiichi Sankyo Co Ltd ADR

N/A

USD 63.77B
ALPMF Astellas Pharma Inc

N/A

USD 21.46B
ALPMY Astellas Pharma Inc

N/A

USD 21.25B
RICFY Recordati Industria Chimica e ..

N/A

USD 11.87B

ETFs Containing KYKOF

1621:TSE NEXT FUNDS TOPIX-17 Pharm.. 0.00 % 0.00 %

+160.00 (+0.55%)

USD 2.53B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - General) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 25.20% 85% B 75% C
Dividend Return 1.17% 26% F 17% F
Total Return 26.37% 91% A- 74% C
Trailing 12 Months  
Capital Gain 19.70% 73% C 67% D+
Dividend Return 2.29% 47% F 33% F
Total Return 21.99% 76% C+ 66% D+
Trailing 5 Years  
Capital Gain 13.97% 71% C- 67% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 13.97% 59% D- 64% D
Average Annual (5 Year Horizon)  
Capital Gain -2.40% N/A N/A 34% F
Dividend Return -1.06% N/A N/A 33% F
Total Return 1.35% N/A N/A 30% F
Risk Return Profile  
Volatility (Standard Deviation) 24.15% N/A N/A 81% B-
Risk Adjusted Return -4.38% N/A N/A 32% F
Market Capitalization 11.02B 50% F 91% A-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced on cashflow basis

The stock is trading low compared to its peers on a price to cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Poor return on equity

The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.